Chondroitin Sulfate

Summary

Chondroitin Sulfate (CHEMBL2303614) is a phase-3 clinical-stage small molecule; indicated across 1 condition including osteoarthritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 14
• Chemistry: 531.5 Da · C19H33NO14S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2303614
Name	Chondroitin Sulfate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	71720239
Molecular formula	C19H33NO14S
Molecular weight	531.5
InChIKey	OAEOAAHCJGWJIC-CEVJMMQXSA-N

SMILES: CC(=O)N[C@H]1[C@@H](O[C@@H]([C@@H]([C@@H]1COC[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)CO)O)O)CS(=O)(=O)O)CO)CO

IUPAC name: (2S,3S,4S,5R,6S)-6-[[(2R,3R,4S,5R,6S)-3-acetamido-2,6-bis(hydroxymethyl)-5-(sulfomethyl)oxan-4-yl]methoxymethyl]-4,5-dihydroxy-3-(hydroxymethyl)oxane-2-carboxylic acid

Also known as: Chondroitin sulfate, CHONDROITIN SULFATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis	3	MONDO:0005178	MONDO:0005178

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	6
PHASE3	4
PHASE4	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00805519	PHASE4	COMPLETED	Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee
NCT01233739	PHASE4	UNKNOWN	Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.
NCT00032890	PHASE3	COMPLETED	Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
NCT01293305	PHASE3	UNKNOWN	Study With Chondroitin Sulfate and Glucosamine Sulfate (in Dosage Capsule and Sachet) in Treating Osteoarthritis
NCT01354145	PHASE3	COMPLETED	Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI
NCT02079727	PHASE3	COMPLETED	Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
NCT01245088	PHASE1/PHASE2	WITHDRAWN	Chondroitin Sulfate for Crohn’s Disease
NCT06547424	PHASE1	WITHDRAWN	Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC
NCT01469507	Not specified	WITHDRAWN	Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis
NCT01813565	Not specified	TERMINATED	The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.
NCT03463499	Not specified	COMPLETED	The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
NCT04654871	Not specified	COMPLETED	Effects of Glucosamine and Chondroitin Sulfate Supplementation in Addition to Resistance Exercise Training and Manual Therapy in Patients With Knee Osteoarthritis
NCT05385562	Not specified	COMPLETED	Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
NCT06623773	Not specified	COMPLETED	Study on Structum® in Adult Patients With Osteoarthritis (TRUST)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).